Model of minimal residual disease. Model of minimal residual disease. A–G, Histologic sections. A, Skin at the site of B16 cell injection from a C57BL/6 mouse treated with Pmel adoptive T-cell therapy with VSV-gp100 viro-immunotherapy (34). B–D, Skin explants from the site of B16tk cell injection from mice treated with ganciclovir (no palpable tumor after regression) were left untreated (B), cocultured with 105 splenocytes and lymph node cells from normal C57BL/6 mice (C), or cocultured with 105 splenocytes and lymph node cells from C57BL/6 mice cleared of B16tk tumors after ganciclovir treatment (D). Seven days later, wells were inspected for actively growing tumor cells. Images are representative of nine independent experiments with explants from different primary treatments. E–H, Skin from the sites of cleared B16tk tumors were explanted and treated as in B and were cocultured with VEGF (E; 12 ng/mL), VEGF and 105 splenocytes and lymph node cells from normal C57BL/6 mice (F), or VEGF and 105 splenocytes and lymph node cells from C57BL/6 mice cleared of B16tk tumors after ganciclovir treatment (G). Three separate explants per treatment were counted. H, Quantitation of B–G. Tim Kottke et al. Cancer Immunol Res 2017;5:1029-1045 ©2017 by American Association for Cancer Research